Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Effect of CYP3A4 Inhibitors on PF-00489791 PK
NCT02319148Phase 1Completed
- Sponsor
- Pfizer
- Start
- Jul 2014
- Primary completion
- Oct 2014
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of PF-00489791 in diabetic nephropathy (DN) and hypertension (HTN) (4 arms), sponsored by Pfizer. Primary endpoints: Maximum Observed Plasma Concentration and Area Under the Plasma Concentration-Time Profile From Time 0 Extrapolated to Infinite Time. Started Jul 2014; status: completed.
02
Drugs
PF-00489791
03
Conditions
diabetic nephropathy (DN)hypertension (HTN)
Beyond the preview
Go deeper on NCT02319148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02319148.